Needham Comments on Other Stocks in RNAi Following Merck's Deal to Buy Sirna Therapeutics
Tweet Send to a Friend
Commenting on the implications of Merck's (NYSE: MRK) acquisition of RNAi company Sirna Therapeutics (Nasdaq: RNAI), at a 102% premium ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
